| First Author | Vandenabeele M | Year | 2021 |
| Journal | Acta Neuropathol Commun | Volume | 9 |
| Issue | 1 | Pages | 6 |
| PubMed ID | 33407903 | Mgi Jnum | J:311730 |
| Mgi Id | MGI:6771457 | Doi | 10.1186/s40478-020-01102-5 |
| Citation | Vandenabeele M, et al. (2021) The App(NL-G-F) mouse retina is a site for preclinical Alzheimer's disease diagnosis and research. Acta Neuropathol Commun 9(1):6 |
| abstractText | In this study, we report the results of a comprehensive phenotyping of the retina of the App(NL-G-F) mouse. We demonstrate that soluble Abeta accumulation is present in the retina of these mice early in life and progresses to Abeta plaque formation by midlife. This rising Abeta burden coincides with local microglia reactivity, astrogliosis, and abnormalities in retinal vein morphology. Electrophysiological recordings revealed signs of neuronal dysfunction yet no overt neurodegeneration was observed and visual performance outcomes were unaffected in the App(NL-G-F) mouse. Furthermore, we show that hyperspectral imaging can be used to quantify retinal Abeta, underscoring its potential as a biomarker for AD diagnosis and monitoring. These findings suggest that the App(NL-G-F) retina mimics the early, preclinical stages of AD, and, together with retinal imaging techniques, offers unique opportunities for drug discovery and fundamental research into preclinical AD. |
